What is the project?

Verily has a robust nanoparticle R&D program that features a scalable platform for synthesis, characterization, and high-throughput screening of particles with predictable physicochemical properties. Verily and Verve Therapeutics are employing this platform to develop and optimize new gene editing delivery vehicles for treatment of coronary artery disease.

How are you making it happen?

Verily's nanoparticle program is focused on lipid-based nanoparticles (LNPs and liposomes), the most widely used nanocarriers for drug delivery. LNPs are flexible, allowing for attachment of targeting groups such as antibodies or peptides to their surface, and amenable to a diversity of payloads, including nucleic acids. When properly designed, LNPs can deliver their therapeutic payload into a cell, which requires it to fuse with the cell membrane, and avoids cell degradation. The program includes an automated high throughput platform that allows synthesis of nanoparticle libraries using a combinatorial chemistry approach. Verily has also invested in and optimized instrumentation for in-depth, high throughput characterization and data capture on all of the particles we produce to develop a clear picture of the physical characteristics and chemical composition of the particles (i.e. size, charge, stability) and the impact they have on biological behaviors. This includes assessing binding to specific cell types, toxicity, tissue penetration, and so on. In addition to this high throughput in vitro screening, Verily has developed a proprietary method of "barcoding" unique particle formulations to conduct in vivo studies in what we anticipate will be a faster and more efficient manner. By gathering all of this information on the chemistry, the physical characteristics, in vitro assay results, and in vivo study results, we are building a data analysis pipeline to more efficiently design and synthesize particles in the future.

Learn more in our newsroom